her2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer
Published 8 years ago • 961 plays • Length 5:31Download video MP4
Download video MP3
Similar videos
-
5:39
ductal carcinoma in situ: anastrozole versus tamoxifen
-
2:30
prognostic value of her2-low status in breast cancer: a systematic review and meta-analysis
-
24:22
tamoxifen and aromatase inhibitor comparison | case based learning | drugs for breast carcinoma
-
6:28
professor mitch dowsett - tamoxifen vs aromatase inhibitors
-
10:39
gs2-04: "aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor..."
-
6:13
adjuvant exemestane more effective than tamoxifen (combined with ofs) in women with breast cancer
-
6:32
no significant difference in recurrence rates among women with dcis taking anastrozole or tamoxifen
-
46:29
tamoxifen and aromatase inhibitors
-
0:27
how to cope with tamoxifen and letrozole
-
1:13
dr. pagani discusses aromatase inhibitors for premenopausal women with breast cancer
-
7:08
selective oestrogen receptor degraders as treatment for er positive/her2 negative advanced/metas...
-
4:07
new advances in hormonal therapies for er-positive breast cancer
-
7:06
everolimus extends pfs for hr positive, her2 negative breast cancer
-
7:11
updates on hormone receptor-positive her2-negative breast cancer
-
0:53
final results of the phase 3 data trial assessing aromatase inhibition in hr breast cancer
-
3:13
ac versus taxac in high-risk her2-negative mbc
-
1:10:36
updates in extended endocrine therapy for hr breast cancer | asco21 & national practice guidelines
-
1:08:15
hormone receptor-positive and her2-positive breast cancer: a medical update
-
10:16
endocrine therapy, tamoxifen & aromatase inhibitors